Skip to main content
. 2009 May 26;27(21):3430–3436. doi: 10.1200/JCO.2008.18.4085

Fig 2.

Fig 2.

Disease-free survival by cyclophosphamide, doxorubicin, and fluorouracil (CAF) dose in HER2 amplified and nonamplified tumors. Kaplan-Meier estimates were calculated using SAS 9.1 for disease-free survival by CAF dose (low, moderate, high) for HER2 amplified versus HER2 nonamplified tumors. P = .079, interaction term for the three arms.